

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trad mark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE MAILED:

APPLOATION, NOTE FILING PATS / O FASTARRST NAMED INVENTOR	R ATTORNEY DOCKET NO. I 15280-259120
020350 HM11/0830 - TOWNSEND AND TOWNSEND AND CREW TWO EMBARCADERO CENTER E1GHTH FLOOR SAN FRANCISCO CA 94111-3834	EXAMINER HOLLERAN, A ART UNIT PAPER NUMBER
94411-3834	1642 08/30/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Africe

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ FILING DATE FIRST NAMED INVENTOR / ATTORNEY DOCKET NO. PATENT IN REEXAMINATION

EXAMINER

ART UNIT

PAPER

6

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Holleran, Art Unit 1642, whose telephone number is 703 308-8892.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Anne Holleran Patent Examiner July 26, 2001

ANTHONY C CAPITA

IPERVIUM "MEF

TEChicompan dering of d

Notice to Comply With Sequenc	Rules	Application No.	Applicant(s)			
		09/684,599	PASTAN ET AL.			
		Examin r	Art Unit			
		Anne Holleran	1642			
NOTICE TO COMPLY WITH REQUIREMEN			CONTAINING NUCLEO	TIDE		
SEQUENCE AND/OR AMINO ACID SEQUE	NCE DISC	CLOSURES				
The nucleotide and/or amino acid sequence of for such a disclosure as set forth in 37 C.F.R.				he requirements		
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 8230, May 1, 1990.						
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).						
3. A copy of the "Sequence Listing" in Computer Readable Form (CRF) has not been submitted as required by 37 C.F.R. 1.821(e).						
4. A copy of the "Sequence Listing" in Computer Readable Form (CRF) has been submitted. However, the content of the CRF does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."						
5. The Computer Readable Form (CRF) that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute CRF must be submitted as required by 37 C.F.R. 1.825(d).						
6. The paper copy of the "Sequence Listing" is not the same as the Computer Readable Form (CRF) of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).						
7. Other:			<u>. </u>			
Applicant Must Provide:						
••						
An initial or substitute copy of the CRF	"Sequence	Listing".				
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.						
A statement that the content of the paper and CRF copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).						
For questions regarding compliance to the	ese requir	rements, please contact:				
For Rules Interpretation, call (703) 308-4	216					
For CRF Submission Help, call (703) 308-4212						
PatentIn Software Program Support (SIR.			•			
Technical Assistance						
To Purchase PatentIn Software		703-306-2600		:		